Nicola Montani

Crowell & Moring Partner Sadina Montani Running for D.C. Bar President-Elect

Retrieved on: 
Monday, March 18, 2024
Community, Homelessness, Organization, Disability, Labour, WBA, Environment, Trust, Greater, Education, Committee, Lawyer, Crowell & Moring, Washington, D.C., Leadership development, Supreme court, Nicola Montani, Community of Hope, Supreme, National Association, Nursing

WASHINGTON, March 18, 2024 /PRNewswire/ -- Crowell & Moring is proud to announce that Sadina Montani has been nominated by the D.C. Bar Committee on Nominations to become president-elect of the D.C. Bar for the 2024-2025 term.

Key Points: 
  • WASHINGTON, March 18, 2024 /PRNewswire/ -- Crowell & Moring is proud to announce that Sadina Montani has been nominated by the D.C. Bar Committee on Nominations to become president-elect of the D.C. Bar for the 2024-2025 term.
  • "All of us at Crowell are extremely proud of this recognition of Sadina's long and deep record of leadership and service in the Washington, D.C. bar," said Philip T. Inglima , chair of Crowell & Moring.
  • "The latest expression of trust from the D.C. Bar Committee on Nominations advances the opportunity for Sadina to follow in a long tradition of D.C. Bar leadership by Crowell partners.
  • Montani has held numerous voluntary leadership positions with bar organizations, legal services providers and community nonprofits.

AccuStem’s StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort

Retrieved on: 
Tuesday, March 1, 2022
GLOBE, Risk, European Journal of Cancer, European Organisation for Research and Treatment of Cancer, Comparison, European Institute of Oncology, ATAC, European Institute, S, Research, Industry, Breast cancer, Biology, EJC, EORTC, Health, OTC, Regulation, European Journal, Treatment, Woman, European Society for Medical Oncology, Recurrence, Forward-looking statement, Carcinogenesis, Patient, IEO, The Royal Marsden NHS Foundation Trust, Nicola Montani, Epidemiology, SPRS, P, Royal Marsden Hospital, Pharmaceutical industry, Cancer, PHOENIX

Results demonstrate that StemPrintER is highly prognostic for risk of distant recurrence in women with breast cancer.

Key Points: 
  • Results demonstrate that StemPrintER is highly prognostic for risk of distant recurrence in women with breast cancer.
  • The pivotal TransATAC study has been used to evaluate many of the commonly used breast cancer risk scoring assays, including OncotypeDX, Prosigna, EndoPredict and Breast Cancer Index.
  • In this analysis, investigators demonstrated that patients with a StemPrintER Risk Score (SPRS) Low result had significantly better outcomes than patients with a SPRS High result.
  • Comparison of stemprinter with Oncotype DX recurrence score for predicting risk of breast cancer distant recurrence after endocrine therapy.